Johnson & Johnson Medtech bags USFDA approval for updated Varipulse Platform Irrigation Rate

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-07-15 08:00 GMT   |   Update On 2025-07-15 08:00 GMT
Advertisement

New Brunswick: Johnson & Johnson MedTech has announced the U.S. Food and Drug Administration (FDA) approval of an update to the VARIPULSE pulsed field ablation (PFA) Platform’s irrigation flow rate.

“By learning from real-world experience and working closely with clinicians, we are continuously enhancing our technologies to improve patient care,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, Johnson & Johnson MedTech. “This update to the VARIPULSE Platform reflects our ongoing commitment to lead the evolution of PFA through meaningful, data-driven improvements that advance product performance and build procedural confidence.”

This approval follows Johnson & Johnson MedTech’s milestone of surpassing 10,000 VARIPULSE procedures across the U.S., Europe, Canada, Japan, Hong Kong, China, Korea, Taiwan, and Australia. Notably, the platform has sustained a neurovascular adverse event rate of less than 0.5%.

Read also: Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International

The VARIPULSE Platform is Johnson & Johnson MedTech’s Pulsed Field ablation system. The fully integrated platform includes the VARIPULSE Catheter, TRUPULSE Generator, and CARTO 3 Mapping System VARIPULSE Software. The Platform is now approved for use in the United States, Europe, Asia Pacific, and Canada.

Read also: JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation the company is addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. Johnson & Johnson MedTech specializes in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care.

Read also: JnJ Orthopaedics Company DePuy Synthes gets 510(k) FDA clearance of VELYS Robotic-Assisted Solution for use in Unicompartmental Knee Arthroplasty Procedures

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News